Silence Therapeutics

London, United Kingdom Founded: 1999 • Age: 27 yrs Listed
RNA therapeutics for hematology and cardiovascular diseases are developed.

About Silence Therapeutics

Silence Therapeutics is a publicly listed company based in London (United Kingdom) founded in 1999. RNA therapeutics for hematology and cardiovascular diseases are developed. It operates in the Healthcare and Technology sectors. The company has 116 employees. Silence Therapeutics has completed 1 acquisition, including Intradigm Corporation. Its website silence-therapeutics.com draws about 14 thousand monthly visits. Its focus areas include High Tech, Nanotechnology, Nanotools and Genomics. Its legal entity is SILENCE THERAPEUTICS PLC.

Company details

Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.

  • Headquarters London, United Kingdom
  • Employees 116
  • Stage Public
  • Sectors
    Healthcare
    Technology
  • Website silence-therapeutics.com
  • Social LinkedIn X
  • Legal Name Silence Therapeutics, Plc.
Key Metrics
  • Annual Revenue
    $559 K (USD)
    -98.71
    as on Dec 31, 2025
  • Net Profit
    -$88.61 M (USD)
    -95.57
    as on Dec 31, 2025
  • EBITDA
    -$81.73 M (USD)
    -66.84
    as on Dec 31, 2025
  • Latest Funding Round
    $120M (USD), Post-IPO

    May 2021

  • Investors
  • Employee Count
    116
  • Investments & Acquisitions

Funding Insights of Silence Therapeutics

  • Total Rounds 11
  • Last Round Post-IPO β€” $120M
  • First Round $24.3M

    (Dec 2009)

  • Investors Count 6

Latest 10 of 11 funding rounds of Silence Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2021$120MPost-IPO––
Feb 2021$45.5MPost-IPO––
Apr 2020$99.07MPost-IPO––
Jul 2019$5MPost-IPO––
Apr 2015$58.2MPost-IPO––
–
Apr 2014$18.95MPost-IPO––
–
Apr 2013$28MPost-IPO––
–
Nov 2012$8MPost-IPO––
–
Jul 2012$8.5MPost-IPO––
–
May 2011$9.6MPost-IPO––
–
Valuation history

6 investors in total: 6 institutional.

Investors in Silence Therapeutics

Silence Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Astrazeneca, Mallinckrodt Pharmaceuticals and Adage Capital Management.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
US private equity investments are managed by BVF Partners.
bvflp.comSan Francisco, United States
consonancecapital.com
Private equity firm focused on company buyouts
gppfunds.comGreenwich, United States
Pharmaceutical and biologics products are developed and distributed worldwide.
1913astrazeneca.comCambridge, United Kingdom
Offers investment management and secure information access to clients and partners.
2001adagecapital.comBoston, United States
Specialty pharmaceutical products and diagnostic imaging agents are manufactured.
1867mallinckrodt.comSt. Louis, United States
Premium access

Investor details for Silence Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Silence Therapeutics

46 people are tracked at Silence Therapeutics (22 in leadership, 12 in board & advisors, 12 in team); the tracked headcount is 116.

NameRoleGroup
J.P. Gabriel
Chief Technical Operations OfficerLeadership
Rhonda Hellums
CFOLeadership
Clare Elliott Cgma Acma
Senior Director, Head Of Fp&aLeadership
Alberto Martinez
Senior Clinical Science DirectorLeadership
Henry Fok
Senior Director, Clinical ScienceLeadership
Lance Edwards
Vice President - Information TechnologyLeadership
John Paul Gabriel
Svp, Chief Technical Operations OfficerLeadership
Craig Tooman
President, CEO & Executive DirectorLeadership
Gianine Abbattista Esposito
Svp, Chief Human Resources OfficerLeadership
Eliot Morrison
Principal Scientist, Head Of Molecular Design BiologyLeadership
Gareth Rees
Associate Director Clinical OperationsLeadership
Rachael Mills
Vp, Head Of Clinical OperationsLeadership
Marianna Anesti
Vice President Of Business DevelopmentLeadership
Curtis Rambaran
Chief Medical Officer, SVPLeadership
Lucas Bethge
Vp, Group Leader Oligonucleotide ChemistryLeadership
David Rider
Project DirectorLeadership
Manuela Aleku
Project DirectorLeadership
Olubunmi Oduwole
Associate Director Clinical OperationsLeadership
Lavita Menezes
Director Clinical OperationsLeadership
Joana Santos
Associate Director Business DevelopmentLeadership

26 more people are available in the full profile.

Premium access

Complete people profiles for Silence Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Silence Therapeutics

Silence Therapeutics is a publicly listed company on the OTC with ticker symbol SLNCF in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date20 Aug 2020
  • Listed onNASDAQ: SLN
  • Listed entitySilence Therapeutics, Plc.
  • Exchange sectorCommercial services
  • ISINGB00B9GTXM62
  • Share price$2.63 (+11.44% on the day) · 2026-05-11
  • Market capitalisation$329.2M
  • EPS (diluted, trailing year)$-0.53
  • Volume (last session)122
  • Analyst consensusNo rating

Financials of Silence Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$559,000-$88.6M-$81.7M
2024$43.3M-$45.3M-$49.0M
2023$31.6M-$54.2M-$51.8M
2022$21.6M-$49.9M-$59.3M
2021$17.1M-$54.2M-$62.4M
Premium access

Detailed financial statements for Silence Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Silence Therapeutics

Silence Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intradigm Corporation.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Develops RNA interference (RNAi) therapeutics for the treatment of cancer.
intradigm.comPalo Alto, United States2000Dec 2009β€’β€’β€’β€’
Premium access

Complete acquisition details for Silence Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Silence Therapeutics

5 dated milestones of Silence Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.

  1. Founded Silence Therapeutics is founded.
  2. Funding First funding round of $24.3M.
  3. Acquisition Acquires Intradigm Corporation.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO, of $120.0M.

Web traffic of Silence Therapeutics

The website of Silence Therapeutics (silence-therapeutics.com) receives about 13.8K visits a month.

  • Monthly visits
    13.8K

    ▲ 96.6% vs previous month

Similar websites

Websites whose visitors overlap most with Silence Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
atugen.com
atugen.com
100%
#14,513,602–
benitec.com
100%
2.7K#6,325,279View details
sylentis.com
99%
3.9K#4,931,838View details
rnaiweb.com
rnaiweb.com
99%
–
oligoengine.com
oligoengine.com
99%
#12,501,139–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for Silence Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

2 companies that operate in the same segment as Silence Therapeutics (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Nanopore-based electronic systems for single-molecule analysis are developed.
2005Oxford, Oxfordshire, United KingdomUSD 1.34 BUSD 301.49 M1,372
Genetically modified cell lines are developed using AAV gene-editing platform.
2007Cambridge, Cambridgeshire, United KingdomUSD 46.29 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Silence Therapeutics

Premium access

Complete news archive for Silence Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Silence Therapeutics

Silence Therapeutics was founded in 1999 and raised its 1st funding round 10 years after it was founded.

Silence Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Silence Therapeutics has 116 employees.

Annual revenue of Silence Therapeutics is $559K as on Dec 31, 2025.

Founded in 1999 and headquartered in London, United Kingdom, RNA therapeutics are developed by the company for hematology and cardiovascular diseases. The pipeline features gene silencing approaches, including one that targets the Lipoprotein(A) gene to reduce risks of heart disease and stroke, and another that silences the TMPRSS6 gene to regulate iron levels in the body. Operations focus on advancing these treatments through clinical development.

Yes, Silence Therapeutics is publicly traded on OTC under the ticker symbol SLNCF.

Silence Therapeutics has made 1 acquisition, including Intradigm Corporation.

Silence Therapeutics has 6 investors. Key investors include Astrazeneca, Mallinckrodt Pharmaceuticals, Adage Capital Management, BVF Partners, and Consonance Capital.

Silence Therapeutics operates through Silence Therapeutics Plc.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available